IKS Health Revenue Doubles to Rs 1,592.478 Crore in September

Inventurus Knowledge Solutions Limited, referred to as IKS Health, reported consolidated revenue from operations of Rs 1,592.478 crore for the quarter ended September 30, 2026, up 103.7% from Rs 781.091 crore a year earlier, while profit for the period rose 18.1% to Rs 213.371 crore.

How did IKS Health perform in the September 2026 quarter?

IKS Health more than doubled consolidated revenue in the quarter ended September 30, 2026, reporting Rs 1,592.478 crore against Rs 781.091 crore in the quarter ended September 30, 2025. Revenue was also above Rs 893.629 crore in the quarter ended June 30, 2026, while the year-on-year increase was Rs 811.387 crore.

Profit before tax was Rs 273.206 crore in the September 2026 quarter, compared with Rs 227.708 crore a year earlier and Rs 250.944 crore in the June 2026 quarter. Profit for the period was Rs 213.371 crore, up from Rs 180.719 crore in September 2025 and Rs 193.741 crore in June 2026.

Why did IKS Health profit rise more slowly than revenue?

The filing does not state why IKS Health’s profit grew more slowly than revenue in the September 2026 quarter. Revenue rose 103.7% year on year to Rs 1,592.478 crore, whereas profit for the period increased 18.1% to Rs 213.371 crore and profit before tax increased 20.0% to Rs 273.206 crore.

Based on the reported consolidated figures, profit for the period was 13.4% of revenue in September 2026, compared with 23.1% in September 2025. This is a calculation from the reported figures, not a margin disclosed by IKS Health, and the newspaper extract provides no segment-wise revenue, cost breakdown or stated explanation for the change.

Total comprehensive income moved differently from profit for the period, declining year on year to Rs 248.731 crore from Rs 267.822 crore despite increasing from Rs 239.973 crore in June 2026. The reported total comprehensive income measure includes profit for the period and other comprehensive income, so it is distinct from the net-profit comparison.

What do IKS Health’s half-year results show?

IKS Health reported consolidated revenue from operations of Rs 2,486.107 crore for the half year ended September 30, 2026, up 63.4% from Rs 1,521.186 crore in the corresponding half year of 2025. The six-month revenue total includes the quarters ended June 30, 2026 and September 30, 2026.

Consolidated profit before tax rose 24.0% to Rs 524.150 crore from Rs 422.590 crore in the prior-year half year. Profit for the period increased 22.5% to Rs 407.112 crore from Rs 332.258 crore, again growing at a lower rate than revenue.

For comparison with the preceding full year, IKS Health reported revenue from operations of Rs 3,193.788 crore and profit for the year of Rs 721.554 crore for the year ended March 31, 2026. The September 2026 half-year revenue was about 77.8% of that earlier full-year revenue, but the filing gives no forecast or target for the year ending March 31, 2027.

How did IKS Health standalone results compare with consolidated results?

IKS Health’s standalone revenue from operations was Rs 378.865 crore in the September 2026 quarter, compared with consolidated revenue of Rs 1,592.478 crore. Standalone revenue was Rs 355.691 crore in September 2025, representing growth of 6.5%, versus consolidated revenue growth of 103.7%.

Standalone profit for the period was Rs 96.267 crore in September 2026, down from Rs 138.399 crore in September 2025 and Rs 162.546 crore in June 2026. This contrasts with consolidated profit for the period, which rose to Rs 213.371 crore from Rs 180.719 crore a year earlier.

The announcement defines the consolidated results as those of IKS Health, its subsidiaries and its interest in an associate, while standalone results cover the company. Standalone profit before tax was Rs 123.487 crore in September 2026, compared with Rs 167.971 crore a year earlier, while consolidated profit before tax increased to Rs 273.206 crore from Rs 227.708 crore.

What were IKS Health’s earnings per share and share-capital figures?

IKS Health reported consolidated basic earnings per share of Rs 12.98 and diluted earnings per share of Rs 12.72 for the quarter ended September 30, 2026. The corresponding September 2025 figures were Rs 10.81 basic and Rs 10.58 diluted, while the reported share capital was Rs 17.091 crore, compared with Rs 17.044 crore a year earlier.

Standalone basic earnings per share were Rs 5.74 in September 2026, down from Rs 8.26 in September 2025, and diluted earnings per share were Rs 5.63 versus Rs 8.06. The board approved the unaudited standalone and consolidated results on November 5, 2026, after review and recommendation by the audit committee.

Conclusion

The September-quarter figures show a substantial expansion in IKS Health’s consolidated revenue, with revenue increasing by Rs 811.387 crore year on year, while profit for the period increased by Rs 32.652 crore. The same pattern appeared over the half year, and the contrast between rising consolidated profit and lower standalone profit is another feature of the reported results.

What remains unresolved is the reason for the differing revenue and profit growth rates, because the filing provides neither a segment-wise revenue or cost split nor a specific explanation. IKS Health also provided no revenue or profit guidance for the year ending March 31, 2027, making subsequent disclosures relevant for assessing whether the reported gap persists.